BridgeBio Pharma Elects New Directors, Discloses Executive Compensation
Ticker: BBIO · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: BBIO
TL;DR
BridgeBio adds 2 directors to the board, filing also touches on exec pay.
AI Summary
BridgeBio Pharma, Inc. announced on July 23, 2024, a change in its board of directors, with Dr. Philip P. Brooks and Dr. Jonathan M. Fleming being elected as Class II directors. Additionally, the company disclosed compensatory arrangements for its named executive officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while executive compensation details are crucial for understanding how leadership is incentivized.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance updates and executive compensation disclosures, with no immediate financial or operational risks indicated.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- Dr. Philip P. Brooks (person) — Elected Class II Director
- Dr. Jonathan M. Fleming (person) — Elected Class II Director
- July 23, 2024 (date) — Date of Report
FAQ
Who were the newly elected directors for BridgeBio Pharma, Inc.?
Dr. Philip P. Brooks and Dr. Jonathan M. Fleming were elected as Class II directors.
What is the effective date of the reported changes?
The date of the earliest event reported is July 23, 2024.
What specific compensatory arrangements were disclosed for named executive officers?
The filing indicates that compensatory arrangements for certain officers were disclosed, but the specific details are not provided within this document.
In which state was BridgeBio Pharma, Inc. incorporated?
BridgeBio Pharma, Inc. was incorporated in Delaware.
What is the principal executive office address for BridgeBio Pharma, Inc.?
The principal executive offices are located at 3160 Porter Dr., Suite 250, Palo Alto, CA 94304.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2024-07-23 16:12:59
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
Filing Documents
- ef20032871_8k.htm (8-K) — 36KB
- ef20032871_ex99-1.htm (EX-99.1) — 9KB
- image0.jpg (GRAPHIC) — 59KB
- 0001140361-24-033856.txt ( ) — 263KB
- bbio-20240723.xsd (EX-101.SCH) — 4KB
- bbio-20240723_lab.xml (EX-101.LAB) — 21KB
- bbio-20240723_pre.xml (EX-101.PRE) — 16KB
- ef20032871_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Following approval by the Board of Directors (the "Board") of BridgeBio Pharma, Inc. (the "Company"), Thomas Trimarchi was appointed as the Company's President and Chief Operating Officer, and Neil Kumar, Ph.D. stepped down as President, in each case, effective as of July 23, 2024. Mr. Trimarchi was appointed to serve as President and Chief Operating Officer until his successor is duly elected and qualified, or until his earlier death, resignation, retirement, removal or termination of office. Dr. Kumar will continue to serve and perform his duties as a director and the Company's Chief Executive Officer. Dr. Trimarchi, age 39, prior to this appointment, served as the Company's Chief Product Officer from April 2018 to July 2024. He has also served on the board of directors of the Company's affiliate ML Bio Solutions, Inc. since November 2021. Prior to joining the Company, Dr. Trimarchi worked in corporate strategy at Regeneron Pharmaceuticals, Inc. from 2017 to 2018, prior to that he was an equity analyst in the Global Investment Research division at Goldman Sachs from 2015 to 2017. Dr. Trimarchi earned his B.S. in Biology from the University of Vermont in 2007, and his Ph.D. in Molecular Oncology and Immunology, Cell and Molecular Biology from New York University in 2014. There are no arrangements or understandings between Mr. Trimarchi and any other persons in connection with his appointment as President and Chief Operating Officer. He has no family relationships with any of the Company's directors or executive officers, and he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended.
01
Item 7.01 Regulation FD Disclosure. On July 23 , 2024, the Company issued a press release announcing Mr. Trimarchi's appointment as President and Chief Operating Officer. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act") or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release dated July 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIDGEBIO PHARMA, INC. Date: July 23, 2024 By: /s/ Brian C. Stephenson Name: Brian C. Stephenson Title: Chief Financial Officer